ReviewCurrent opinion in lipidology2015
Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.
Review in Current opinion in lipidology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.Lipids in health and disease · 2017Pooled it
- Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women.The Journal of clinical endocrinology and metabolism · 2025Trial
- Article
- Review
- Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.Nutrients · 2024Review
- Macrophage polarisation and inflammatory mechanisms in atherosclerosis: Implications for prevention and treatment.Heliyon · 2024Review
- ROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis.Aging and disease · 2024Review
- Coronary artery disease, its associations with ocular, genetic and blood lipid parameters.Eye (London, England) · 2024Article
- The role of foam cells in spinal cord injury: challenges and opportunities for intervention.Frontiers in immunology · 2024Review
- Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics.Acta pharmacologica Sinica · 2023Review
- Atherosclerosis: The Involvement of Immunity, Cytokines and Cells in Pathogenesis, and Potential Novel Therapeutics.Aging and disease · 2023Review
- Inverse Correlation of Cholesterol Efflux Capacity with Peripheral Plaque Volume Measured by 3D Ultrasound.Biomedicines · 2023Article
- Alveolar macrophages in pulmonary alveolar proteinosis: origin, function, and therapeutic strategies.Frontiers in immunology · 2023Review
- Circular RNA circ_0001445 alleviates the ox-LDL-induced endothelial injury in human primary aortic endothelial cells through regulating ABCG1 via acting as a sponge of miR-208b-5p.General thoracic and cardiovascular surgery · 2022Article
- Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal transduction and targeted therapy · 2022Review
- Article
- Circulating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy.Nutrients · 2022Article
- Curcumin attenuates inflammation of Macrophage-derived foam cells treated with Poly-L-lactic acid degradation via PPARγ signaling pathway.Journal of materials science. Materials in medicine · 2022Article
- Bioactive components to inhibit foam cell formation in atherosclerosis.Molecular biology reports · 2022Review
- Natural Flavonoids Derived From Fruits Are Potential Agents Against Atherosclerosis.Frontiers in nutrition · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewRandomized clinical trials provide strong evidence that pharmacological elevation of HDL-cholesterol (HDL-C) fails to reduce cardiovascular disease (CVD) risk in statin-treated humans. It is thus critical to identify new metrics that capture HDL's cardioprotective effects. RECENT
findingsWe review recent evidence that HDL's cholesterol efflux capacity is a strong inverse predictor of incident and prevalent CVD in humans. In light of those findings, we assess the proposal that impaired macrophage cholesterol efflux to HDL contributes to disease risk. We also discuss recent studies implicating small HDL particles in cholesterol efflux from macrophages. SUMMARY: These observations lay the foundation for a new approach to understanding mechanistically how HDL's functional properties help reduce CVD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.